Core Insights - Halozyme Therapeutics is expanding its portfolio with the acquisition of Hypercon and Surf Bio, enhancing its capabilities in subcutaneous (SC) drug delivery technologies [4][5][6] - The company expects significant revenue growth, with preliminary 2025 total revenue estimates between $1.385 billion and $1.4 billion, representing a 36% to 38% increase over 2024 [8] - Halozyme has raised its 2026 guidance, projecting total revenue between $1.71 billion and $1.81 billion, with royalty revenue between $1.13 billion and $1.17 billion [17] Acquisition and Technology Expansion - The acquisition of Surf Bio adds a second hyperconcentration technology, which is expected to be clinic-ready by the end of 2027 or early 2028 [4][7] - Hypercon technology is anticipated to be clinic-ready in 2026, with two partners expected to initiate Phase I studies by the end of 2026 [5][7] - The company now has three royalty-bearing SC delivery technologies, expanding its opportunity set into the mid-2040s [5][6] Financial Performance and Projections - Halozyme's 2025 royalty revenue is projected to be between $865 million and $870 million, reflecting a growth of 51% to 52% over 2024 [8] - For 2026, the company expects to exceed $1 billion in royalty revenue, a year earlier than previously projected [9] - Long-term projections indicate total revenue exceeding $2 billion by 2028, with royalty revenue between $1.46 billion and $1.51 billion, representing a CAGR of 26% to 28% from 2024 to 2028 [11] Product Development and Market Strategy - The company anticipates six new ENHANZE products entering Phase I in 2026, increasing the development portfolio to 13 products [13] - Major product drivers include DARZALEX and VYVGART Hytrulo, with projected sales of $14.3 billion and $4.15 billion respectively for 2025 [13] - Halozyme is exploring additional M&A opportunities to enhance its drug delivery technology and revenue growth [15] Profitability and Operational Efficiency - Halozyme aims for a gross margin above 80% and an operating margin greater than 60% during the 2026–2028 period [12] - The company projects free cash flow to exceed 70% of EBITDA, indicating a strong focus on operational efficiency [12]

As filed with the Securities and Exchange Commission on January 28, 2026. Registration No. 333-292657 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Veradermics, Incorporated (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 84-3304423 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificat ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Tyligand Bioscience Ltd. 泰勵生物有限公司 * (the "Company") (Incorporated in the Cayman Islands with limited liability) WARNING The publication ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Suzhou Genhouse Bio Co., Ltd. 勤浩醫藥（蘇州）股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) WARNING ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Tyligand Bioscience Ltd. 泰勵生物有限公司* (Incorporated in the Cayman Islands with limited liability) WARNING The publication of this announcement is req ...

Core Insights - The FDA has lifted the clinical hold on Intellia Therapeutics' investigational new drug application for the phase III study MAGNITUDE-2, which evaluates nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) [2][5] - Following this regulatory update, Intellia's shares increased by nearly 6.3%, and the company's stock has risen 46.6% over the past year, outperforming the industry average of 17.2% [2] Recent Developments - In October 2025, Intellia halted dosing and patient enrollment in its late-stage MAGNITUDE and MAGNITUDE-2 studies due to a serious adverse event involving a patient who experienced severe liver issues and subsequently died [4] - The FDA's clinical hold was a response to these safety concerns, but Intellia has since aligned with the FDA on study modifications and risk-mitigation measures, including enhanced liver safety monitoring [5][6] Study Details - MAGNITUDE-2 is a randomized, double-blind, placebo-controlled phase III study designed to assess the efficacy and safety of nex-z in patients with ATTRv-PN, with planned enrollment increased from approximately 50 to 60 patients [9] - The primary endpoints of the study include changes in the modified neuropathy impairment score and serum transthyretin levels [9] Collaboration and Financials - Nex-z is Intellia's lead program, developed in partnership with Regeneron Pharmaceuticals, which shares 25% of the R&D costs and profits [6][8] - Intellia's current revenue primarily comes from collaboration with partners like Regeneron, and the drug has received Orphan Drug and Regenerative Medicine Advanced Therapy designations from the FDA [8]

Core Viewpoint - CytoMed Therapeutics Limited addresses and rejects recent misleading claims regarding its research programs, clinical progress, and operations, emphasizing its commitment to transparency and accurate communication [1][2][5]. Company Overview - CytoMed is a clinical stage biopharmaceutical company based in Singapore, focused on developing affordable donor-derived cell-based immunotherapies for various cancers, including blood and solid tumors [1][7]. - The company was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR) [7]. Research and Development - The company's research primarily focuses on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, grounded in established immunological science [3]. - CytoMed's lead CAR γδ T cell program has received regulatory approval for a first-in-human clinical trial, which is currently ongoing at the National University Hospital in Singapore [3]. - Other therapeutic candidates, including iPSC-derived γδ NKT cell candidates, are still in preclinical development [4]. Regulatory and Operational Compliance - CytoMed asserts that it operates in compliance with applicable regulations and follows appropriate development practices for its current stage [5]. - The company emphasizes that any claims regarding its regulatory status, manufacturing capabilities, governance, or financial transparency that contradict its statements are inaccurate or taken out of context [5]. Commitment to Transparency - CytoMed is dedicated to advancing its pipeline responsibly and ensuring timely communication of accurate information through official disclosures [6]. - The company reserves the right to take action against the dissemination of false or misleading information that could harm its reputation or stakeholders [6].

Core Thesis - Argenx SE is experiencing strong momentum driven by the success of its therapy VYVGART, which generated over $4.1 billion in 2025, nearly doubling year-on-year [2][4]. Company Overview - Argenx SE is a commercial-stage biopharma company focused on developing therapies for autoimmune diseases across various countries including the United States, Japan, China, and the Netherlands [2]. Financial Performance - As of January 26th, Argenx's share price was $833.16, with trailing and forward P/E ratios of 35.64 and 27.93 respectively [1]. Product Development and Strategy - VYVGART has evolved into a durable franchise with multiple growth levers, focusing on expanding the addressable patient population rather than just proving demand [4]. - Key priorities for 2026 include broadening VYVGART's global footprint and extending its reach into additional indications such as seronegative and ocular MG, immune thrombocytopenia, myositis, and Sjögren's disease [4]. - The company is also advancing its leadership in FcRn biology through next-generation molecules and new delivery formats, including a planned autoinjector in 2027 [5]. Pipeline and Future Outlook - Argenx is building a robust pipeline with approximately ten registrational studies ongoing and ten molecules in clinical development by year-end, including first-in-class programs [5]. - The company has transitioned from a single-asset biotech to a platform-driven organization, with VYVGART providing scale, cash flow, and credibility, while the growing pipeline reduces concentration risk [6]. - With continued execution, Argenx is positioned as a long-duration immunology compounder with multiple opportunities for sustained value creation [6].

Core Insights - GRI Bio, Inc. announced positive data from its Phase 2a clinical study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF), indicating potential disease-modifying effects and therapeutic differentiation [1][10] Gene Expression and Mechanism - RNA-sequencing data showed significant improvement in genes related to lung injury, myofibroblast activation, and fibrosis progression in GRI-0621 treated subjects compared to placebo, validating previous biomarker findings [2][4] - The treatment demonstrated modulation of differentially expressed genes (DEGs) linked to key disease drivers, supporting a mechanism of fibrosis resolution and tissue repair rather than mere symptomatic management [3][4] Lung Regeneration Evidence - GRI-0621 treatment was associated with repair of the alveolar basement membrane and transition of AT2 to AT1 epithelial cells, indicating true lung regeneration rather than just slowing disease progression [5][6] - Earlier data indicated changes in type IV collagen serum biomarkers, suggesting an alveolar repair mechanism, which is now supported by new gene expression findings [6] Consistency Across Data - The new results reinforce previously announced topline data, showing that GRI-0621 treatment led to decreased neutrophil activity, reduced synthesis of fibrillar collagens, and lower levels of pro-fibrotic cytokines [8][9] - The treatment was well-tolerated, differentiating it from existing options that primarily slow disease decline while having significant side effects [7][10] Clinical Study Outcomes - The Phase 2a study met its primary endpoint with favorable safety and tolerability, and multiple secondary endpoints indicative of disease-modifying activity were achieved [12] - Improvements were noted in forced vital capacity (FVC), with twice as many GRI-0621-treated subjects experiencing no decline in FVC at 12 weeks compared to standard care [12]

Core Insights - Ardelyx, Inc. has initiated the dosing of the first patient in the Phase 3 clinical trial ACCEL for IBSRELA (tenapanor), targeting chronic idiopathic constipation (CIC) in adults [1][2][3] Group 1: Clinical Trial Details - ACCEL is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of tenapanor for CIC, with an enrollment target of approximately 700 patients [2] - The trial will administer tenapanor twice daily for 26 weeks, with primary endpoints focusing on patient-reported outcomes related to constipation [2] - Enrollment is expected to continue throughout 2026, with topline data anticipated in the second half of 2027 [2] Group 2: Company Mission and Progress - Ardelyx aims to discover and commercialize innovative medicines that address significant unmet medical needs, with IBSRELA being a key product in their portfolio [1][11] - The Phase 3 trial represents a strategic move to expand the patient population benefiting from IBSRELA, which has already shown safety and efficacy in treating irritable bowel syndrome with constipation [3][11] Group 3: Market Context - Chronic idiopathic constipation affects over 34 million Americans, significantly impacting quality of life and healthcare costs [4][11] - The global prevalence of CIC is estimated to be between 10-17% of the population, indicating a substantial market opportunity for effective treatments [4][13]